Skip to content
Screener

Willdan Group WLDN Accretion And Fair Value Adjustments Contingent Consideration

Accretion And Fair Value Adjustments Contingent Consideration at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$0-100%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$868K+214%
CS Disco logo
CS DiscoLAW
$0-100%
Flywire Corporation logo
Flywire CorporationFLYW
$490K+173%
The RMR Group logo
The RMR GroupRMR
$0+100%
Insmed logo
InsmedINSM
-$99.76M-269%

Other financials

Income statement

See full
Revenue$231.0M+33.2%
Gross profit$87.5M+28.0%
Operating income$19.7M+67.0%
Net income$24.3M+57.7%
EPS (diluted)$1.58+53.4%

Balance sheet

See full
Cash & equivalents$34.9M+7.8%
Total debt$87.8M+18.2%
Total equity$350.5M+31.8%
Total assets$634.9M+30.9%

Cash flow

See full
Operating cash flow$43.9M+72.7%
CapEx$1.6M-25.4%
Free cash flow$42.2M+82.0%

Valuation

See full
Market cap$1.3B-21.2%
Enterprise value$1.36B-20.0%
P/E20×-27.1×
P/S1.8×-0.9×

Profitability

See full
Gross margin37.8%+0.8pp
Operating margin7.1%+0.9pp
Net margin8.8%+3.2pp
FCF margin8.4%-1.8pp

Returns & leverage

See full
Return on equity21.2%+6.5pp
Debt / equity0.3×0.0×
Current ratio1.4×-0.1×

Where this comes from

Reported directly by Willdan Group in its filing.

Tagged under the XBRL concept wldn:AccretionAndFairValueAdjustmentsContingentConsideration.

The source filing: Willdan Group’s 10-Q, filed August 7, 2026.

Filed
Aug 6, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0001104659-26-092196
Line itemSix Months Ended / July 3, 2026Six Months Ended / July 4, 2025
(Gain) loss on sale/disposal of equipment(43)(23)
Provision for doubtful accounts25279
Stock-based compensation8,5035,608
Accretion and fair value adjustments of contingent consideration1,8281,254
Changes in operating assets and liabilities, net of effects from business acquisitions:
Accounts receivable(12,143)16,898
Contract assets(27,117)(18,062)
Other receivables4,651(2,346)

Item 1. Financial Statements (Unaudited)

FAQ

What is Willdan Group's accretion and fair value adjustments contingent consideration?
Willdan Group (WLDN) reported accretion and fair value adjustments contingent consideration of $925K in Q2 2026.
How has Willdan Group's accretion and fair value adjustments contingent consideration changed year-over-year?
Willdan Group's accretion and fair value adjustments contingent consideration increased by 5.7% year-over-year, from $875K to $925K.
What is the long-term trend for Willdan Group's accretion and fair value adjustments contingent consideration?
Over 3 years (2021 to 2025), Willdan Group's accretion and fair value adjustments contingent consideration has grown at a 9.9% compound annual growth rate (CAGR), from $2.33M to $3.1M.
What does accretion and fair value adjustments contingent consideration mean?
Accretion And Fair Value Adjustments Contingent Consideration as reported by Willdan Group, Inc..

Ask your AI about Willdan Group's accretion and fair value adjustments contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude